Clinical trial NCT05731375: Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
Official title: Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Doxorubicin Induced Cardiomyopathy
Chemotherapeutic Toxicity
B-cell Lymphoma
T-cell Lymphoma
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
Collaborators: name: Julius Clinical
First posted: 2023-02-16
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruited at UMC Utrecht, Diakonessenhuis Utrecht and possibly other hospitals in the vincity of the UMC Utrecht. The aim is to include 12 patients with large B-cell lymphoma or T-cell lymphoma, who are scheduled to undergo (R-)CHOP treatment at any of the recruiting hospitals.

Brief summary: The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and cardiac muscles in muscles in large B- or T-cell lymphoma patients during treatment with (R-)CHOP. The main question it aims to answer is:

• Can 31P-MRS be used to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles in large B- or T-cell lymphoma patients during treatment with (R-)CHOP?

To be able to answer this main question, participants will undergo 31P-MRS imaging of the calf muscles and of the heart 3 times during the study period.

Detailed description: Rationale: Patients with large B-cell lymphoma or T-cell lymphoma are often treated with (R-)CHOP chemotherapy with the intent to cure the disease, but this treatment can also lead to serious toxicities, which may last for many years. (R-)CHOP contains doxorubicin, which has detrimental effects on skeletal and cardiac muscles. Loss of skeletal muscle mass is associated with treatment modifications (i.e., dose delay/reduction/discontinuation), increased levels of fatigue, decreased quality of life (QoL) and shorter survival. Cardiomyopathy might lead to chronic heart failure in the long-term, which negatively affects prognosis as well. Preclinical studies investigating underlying mechanisms of these detrimental effects suggest that mitochondrial dysfunction plays a key role. However, human data is lacking due to the need of invasive repeated muscle biopsies. Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) is an innovative, non-invasive technique, which enables repeated measures of skeletal and cardiac muscle mitochondrial energy metabolism.

Hypothesis:

In this study the investigators hypothesize that patients with large B-cell lymphoma or T-cell lymphoma treated with (R-)CHOP will show decreased mitochondrial function in skeletal and cardiac muscle tissue following chemotherapy treatment.

Objective:

To demonstrate the ability of using non-invasive 31P-MRS to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles (i.e., skeletal muscle PCr recovery rate constant and cardiac PCr/ATP ratio) in patients with large B-cell lymphoma or T-cell lymphoma during treatment with (R-)CHOP. Furthermore, the investigators will assess the feasibility of undergoing the study measurements for patients with large B-cell lymphoma or T-cell lymphoma during intensive (R-)CHOP treatment and explore the association between changes in in vivo measured mitochondrial function in skeletal and cardiac muscle tissue and changes in muscle mass, physical fitness, muscle strength, physical activity levels measured by Fitbit, chemotherapy completion rate and patient-reported outcomes, including physical activity, fatigue and quality of life.

Study design: Cohort study.

Study population: Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6 full-dose cycles of 1st line immunochemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone with or without rituximab ((reversed) (R-)CHOP).

Main study parameters/endpoints:

The main study parameters are differences in skeletal muscle PCr recovery rate constant and cardiac PCr/ATP ratio. These parameters will be compared within-patients before, halfway during and after completion of chemotherapy treatment.

Nature and extent of the burden and risks associated with participation and benefit:

Included patients will visit the UMC Utrecht 3 times (i.e., before, halfway during and after completion of chemotherapy treatment). During these visits, participants will undergo 31P-MRS imaging of the calf muscles and of the heart at 7 Tesla. During the calf muscle scan, patients will be asked to perform a mild exercise challenge (i.e., dynamic plantar flexions). 7T 31P-MRS is a safe and reliable technique for subjects without contra-indications for undergoing MRI. Possible side-effects are limited to short-term vertigo and nausea. In addition, anthropometrics will be measured and small tests to evaluate muscle strength and physical performance will be performed. Participants will be asked to complete questionnaires regarding physical activity, quality of life and fatigue. Finally, patients will be asked to wear a Fitbit, provided by the study team, to objectively assess their levels of physical activity.

Subjects will not experience direct benefits by participating in this study. By the end of the study, the investigators will demonstrate the ability to non-invasively monitor skeletal and cardiac muscle mitochondrial damage using 31P-MRS, which is a pre-requisite to assess the efficacy of (non-)pharmacological interventions.

Eligibility criteria: Inclusion criteria:

* Age ≥ 18 years
* Patients with large B-cell lymphoma or T-cell lymphoma scheduled for 6 full-dose cycles of 1st line immunochemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone with or without rituximab ((reversed) (R-)CHOP).
* WHO-performance score 0-2.
* Patients with sufficient Dutch writing and reading skills.
* Written informed consent.

Exclusion Criteria:

* Contra-indications for 7T MR scanning, including patients with a non-MRI compatible pacemaker, cochlear implant or neurostimulator; patients with non-MR compatible metallic implants in their eye, spine, thorax or abdomen; patients with a non-MR compatible aneurysm clip in their brain; patients with claustrophobia, and/or severe obesity.
* Any circumstances that would impede adherence to study requirements or ability to give informed consent.
* Medical disorders affecting mitochondrial function; e.g., spinal muscular atrophy.
* (Other) relevant medical disorders; e.g., comorbidities affecting exercise tolerance.
* Being under examination for non-diagnosed disease at the time of investigation.

Primary outcomes:
measure: Changes in skeletal and cardiac muscle mitochondrial function
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
Secondary outcomes:
measure: Adherence rates to the study protocol
timeFrame: Baseline to 18 weeks.
measure: Changes in physical fitness (Maximum short exercise capacity (Watt))
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in hand grip strength (kg)
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in leg strength (kg)
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in skeletal muscle area in cm2
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in subjective physical activity levels (min/week moderate-to-vigorous physical activity)
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in objective physical activity levels (min/week moderate-to-vigorous physical activity)
timeFrame: Throughout the whole study, but of particular interest are the 9th week after baseline and 18th week post-baseline
measure: Changes in health-related Quality of Life
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in lymphoma specific symptoms
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in fatigue
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in skeletal muscle end-exercise pH
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Changes in skeletal muscle delta PCr during recovery after exercise in mM
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
Other outcomes:
measure: Changes in weight (kg)
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
measure: Height (cm)
timeFrame: Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)
Locations:
city: Utrecht
country: Netherlands
facility: Diakonessenhuis
city: Utrecht
country: Netherlands
facility: UMC Utrecht
Study officials:
References: